Dechra Financial Statements From 2010 to 2026

Dechra Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Dechra Pharmaceuticals' valuation are provided below:
Dechra Pharmaceuticals PLC does not presently have any fundamental signals for analysis.
Check Dechra Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dechra Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Dechra financial statements analysis is a perfect complement when working with Dechra Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Dechra Pharmaceuticals Technical models . Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Dechra Pharmaceuticals PLC Company Operating Margin Analysis

Dechra Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

 = 

Operating Income

Revenue

X

100

More About Operating Margin | All Equity Analysis

Current Dechra Pharmaceuticals Operating Margin

    
  0.14 %  
Most of Dechra Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dechra Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition

Based on the recorded statements, Dechra Pharmaceuticals PLC has an Operating Margin of 0.1405%. This is 100.4% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The operating margin for all United States stocks is 102.55% lower than that of the firm.

Dechra Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Dechra Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Dechra Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dechra Pharmaceuticals competition to find correlations between indicators driving Dechra Pharmaceuticals's intrinsic value. More Info.
Dechra Pharmaceuticals PLC is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about  0.53  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Dechra Pharmaceuticals PLC is roughly  1.87 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Dechra Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Dechra Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in Dechra Pink Sheet

If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Equity Valuation
Check real value of public entities based on technical and fundamental data
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
CEOs Directory
Screen CEOs from public companies around the world